Lyell(LYEL) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 SOUTH SAN FRANCISCO, Calif., May 13, 2025 -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today reported financial results and business highlights for the first quarter ended March 31, 2025. Lyell's lead clinical program, LYL314 (formerly known as IMPT-314), is an autologous CD19/CD20 dual-targ ...